Physical Examination Findings
Th e patient was a thin-appearing man in no acute distress. Vital signs were as follows: heart rate, 123/min; BP, 139/92 mm Hg; temperature, 37.4°C; respiratory rate, 24/min; and oxygen saturation 97% while on room air. Significant physical examination findings included decreased breath sounds and faint rhonchi in the posterior left upper lung fi eld. Cardiovascular, oropharyngeal, abdominal, and genitourinary examinations were unremarkable.
Diagnostic Studies
Laboratory data on presentation were as follows: WBC, 10 3 / m L; lactic acid, 1.0 mM; CD4 1 count, 237/ m L; HIV viral load, 646. Liver function tests and basic chemistries were unremarkable. Blood and urine cultures were negative. Contrast-enhanced chest CT scan showed a left hilar mass with infi ltration into the proximal left upper lobe bronchi and distal mainstem bronchus ( Fig 1 ) . Left -sided mediastinal and hilar lymphadenopathy were also noted. Th ere was also postobstructive volume loss with patchy centrilobular micronodular opacities in the left upper lobe ( Fig 2 ) . Th e patient underwent fl exible fi ber-optic bronchoscopy, which revealed two friable, polypoid, pearly endobronchial masses causing 80% and 60% obstruction of the left upper and left lower bronchi, respectively ( Fig 3 ) . Histopathologic results are shown ( Figs 4 , 5 ) . 
Discussion
Immune reconstitution infl ammatory syndrome (IRIS) is a rare but increasingly common disorder among patients with HIV in the era of highly active antiretroviral therapy (HAART). Th e paradoxical clinical deterioration of patients with IRIS is due to a robust and dysregulated infl ammatory response to a previously treated or clinically silent underlying opportunistic infection in the setting of restored T-cell function in response to effective antiretroviral therapy. Nontuberculous mycobacteria (NTM) commonly serve as this antigenic reservoir, with M avium complex (MAC) being the most frequently encountered. Of all patients receiving HAART therapy, the incidence of IRIS is estimated at 17% to 32% and the incidence of MAC-associated IRIS is roughly 3.5%. The extent of immunosuppression prior to therapy, degree of viral suppression after therapy, and a marked recovery of CD4 memory T cells following initiation of HAART place patients at a higher risk of developing IRIS. In observational studies of MAC-associated IRIS, the median decline of HIV RNA load is 2.5 log 10 and median increase of T-cell lymphocytes is from 20 cells/ m L to 120 cells/ m L aft er initiation of HAART.
Th e precise pathophysiology of IRIS is not completely understood, but it is likely related to the dramatic reduction in HIV viral load that leads to a biphasic recovery of CD4 cells. Because the half-life of the HIV virus is only 1 to 4 days, it is possible to observe a 90% to 95% decline in viral load and subsequent increase of T lymphocytes in the fi rst 1 to 2 weeks of antiretroviral therapy. A decline in cytokines also leads to a short-term increase in circulating CD4 cells via redistribution of cells previously aggregated in peripheral lymphatic tissues. Long-term rise of the CD4 lymphocyte population is achieved through clonal expansion of naive lymphocytes in the thymus occurring 4 to 6 weeks aft er initiation of HAART. Th is rapidly increased number of CD4 memory T lymphocytes mounts an exuberant local and systemic infl ammatory response to a previously encountered antigen leading to clinical deterioration.
Th e clinical manifestations of NTM-IRIS vary widely but most commonly include peripheral lymphadenopathy, intraabdominal disease including abdominal pain, peritonitis or ascites, and/or pulmonary-thoracic disease. Th e most common symptoms of pulmonary involvement include cough or wheezing (93% of patients), fever (80%), night sweats (73%), and dyspnea (47%). Th e severity of symptoms may range from mild respiratory symptoms to ARDS and respiratory failure. Symptoms may occur as early as 2 weeks aft er initiation of HAART, however, the median interval from therapy to diagnostic procedure is 10 weeks.
Diagnosis of IRIS is particularly diffi cult because there is not a universally accepted set of criteria for its defi nition.
Generally the accepted features that should be present to make a diagnosis include the presence of AIDS with low pretreatment CD4 count, a response to HAART as seen by decreasing viral loads, a clinically signifi cant infl ammatory event, a temporal relationship with the initiation of HAART therapy, and the absence of an alternative cause for the clinical presentation. Th e diagnosis of pulmonary NTM-IRIS oft en requires bronchoscopy with BAL or tissue biopsy. Tissue will show granulomatous inflammation and mycobacteria on acid-fast staining.
Radiographic fi ndings of NTM-IRIS most commonly consist of mediastinal or hilar lymphadenopathy, parenchymal infi ltrates, cavitary lesions, and/or lung nodules. In this patient, CT scan findings included centrilobular micronodular opacities with a tree-in-bud morphology. This is most consistent with a primary bronchiolar infectious process, however, postobstructive pneumonia due to malignancy cannot be ruled out until tissue is collected. Endobronchial lesions may be a characteristic finding of MAC-associated IRIS and frequently result in partial or complete bronchial obstruction. In the proper clinical setting, newly discovered endobronchial lesions should raise suspicion for MAC-associated IRIS.
Treatment of IRIS has not been extensively evaluated, but appropriate antimicrobial treatment alone is oft en adequate in non-life-threatening presentations. HAART should typically be continued except in severe cases. Interruption of HAART and administration of corticosteroids may be required in patients with ARDS or tracheal compression from extensive lymphadenopathy. Although primary and/or secondary prophylaxis has not been shown to confer protection from MAC-associated IRIS, treatment of a diagnosed or suspected opportunistic infection is recommended 2 weeks prior to initiation of HAART to decrease the antigenic substrate for a pathologic infl ammatory response.
Despite short-term morbidity associated with IRIS, long-term outcomes are typically favorable. Patients with IRIS are more likely to have successful viral e17 journal.publications.chestnet.org suppression and immune reconstitution at 24 months of HAART, particularly in patients who adhere to medication regimens.
Clinical Course
Biopsy of this patient's endobronchial lesions showed granulomatous infl ammation and numerous acid-fast bacilli (AFB)-positive mycobacteria within epithelioid lymphocytes. BAL showed 1 1 AFB; nucleic acid amplification was negative for Mycobacterium tuberculosis . Th e patient was started on antimicrobial treatment of MAC with rifabutin, ethambutol, and clarithromycin, and sputum culture subsequently grew M avium-intracellulare scrofulaceum . The patient continued on HAART and MAC therapy upon discharge. He had rapid improvement of his symptoms, and a 6-month follow-up chest CT scan showed complete resolution of the endobronchial disease as well as the lymphadenopathy and micronodular opacities.
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